Does Upfront Therapy with Cytoreductive Surgery and Hipec Confer a Survival Benefit in Patients with Synchronous Gastric Peritoneal Carcinomatosis when Compared with Patients with Metachronous Gastric Peritoneal Carcinomatosis?

Kopanakis N, Vasileiadou D, Efstathiou E, Manou V, Ziras N and Spiliotis J

Department of Surgical Oncology, Metaxa Cancer Hospital, Athens
Department of Oncology, Metaxa Cancer Hospital, Athens

^*Correspondance to: Kopanakis N 

 PDF  Full Text DOI: 10.25107/2474-1647.1228

Abstract

Background: Patients with peritoneal carcinomatosis (PC) of gastric origin have an extremely bad prognosis with a median survival estimate at 1–3 months. Peritoneal carcinomatosis is present at the diagnosis in 5-20% of the patients, and almost 60% of them will present it after curative treatment. Peritoneal carcinomatosis from gastric cancer (GPC) responds poorly to systemic chemotherapy. We studied the efficacy of the upfront treatment with cytoreductive surgery (CRS) and HIPEC in patients with synchronous gastric peritoneal carcinomatosis and in patients with metachronous gastric peritoneal carcinomatosis.Methods: We retrospectively analyzed 14 patients with GPC undergoing CRS/HIPEC the last 10 years. Six patients already presented GPC at the time of the diagnosis and eight of them presented metachronous GPC.Results: CRS/HIPEC was performed for synchronous GPC in 6 patients and metachronous GPC in 8 patients. Kaplan-Meier survival curves demonstrated that survival times between two groups were not statistically different.Conclusion: Upfront treatment with CRS/HIPEC doesn’t seem to confer a survival benefit in patients with synchronous gastric peritoneal carcinomatosis.

Keywords

Gastric cancer; Peritoneal carcinomatosis; HIPEC; Upfront therapy

Cite the article

Kopanakis N, Vasileiadou D, Efstathiou E, Manou V, Ziras N, Spiliotis J. Does Upfront Therapy with Cytoreductive Surgery and Hipec Confer a Survival Benefit in Patients with Synchronous Gastric Peritoneal Carcinomatosis when Compared with Patients with Metachronous Gastric Peritoneal Carcinomatosis? Clin Surg. 2016; 1: 1228.